Efficacy of leflunomide for treatment of immune-mediated polyarthritis in dogs: 14 cases (2006-2008)

Journal of the American Veterinary Medical Association

Volumn 236, Issue 3, 2010, Pages 312-318

  Colopy, Sara A ^a   Baker, Theresa A ^a   Muir, Peter ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOXAZOLE DERIVATIVE; LEFLUNOMIDE; NONSTEROID ANTIINFLAMMATORY AGENT;

ANIMAL; ANIMAL DISEASE; ARTHRITIS; ARTICLE; AUTOIMMUNE DISEASE; DOG; DOG DISEASE; FEMALE; MALE; RETROSPECTIVE STUDY;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; AUTOIMMUNE DISEASES; DOG DISEASES; DOGS; FEMALE; ISOXAZOLES; MALE; RETROSPECTIVE STUDIES;

ANIMALIA; CANIS FAMILIARIS;

EID: 76349118744     PISSN: 00031488     EISSN: None     Source Type: Journal    
DOI: 10.2460/javma.236.3.312     Document Type: Article

References (37)

1. Pedersen NC, Weisner K, Castles JJ, et al. Noninfectious canine arthritis: the inflammatory, nonerosive arthritides. J Am Vet Med Assoc 1976;169:304-310.
2. Bennett D. Immune-based non-erosive inflammatory joint disease of the dog. 3. Canine idiopathic polyarthritis. J Small Anim Pract 1987;28:909-928.
3. Gorman NT, Werner LL. Immune-mediated diseases of the dog and cat. I. Basic concepts and the systemic immune-mediated diseases. Br Vet J 1986;142:395-402.
4. Jacques D, Cauzinille L, Bouvy B, et al. A retrospective study of 40 dogs with polyarthritis. Vet Surg 2002;31:428-434.
5. Clements DN, Gear RN, Tattersall J, et al. Type I immune-mediated polyarthritis in dogs: 39 cases (1997-2002). J Am Vet Med Assoc 2004;224:1323-1327.
6. Stull JW, Evason M, Carr AP, et al. Canine immune-mediated polyarthritis: clinical and laboratory findings in 83 cases in western Canada (1991-2001). Can Vet J 2008;49:1195-1203.
7. Bennett D. Treatment of the immune-based inflammatory arthropathies of the dog and cat. In: Kirk RW, Bonagura JD, eds. Current veterinary therapy XII. Philadelphia: WB Saunders Co, 1995;1188-1196.
8. Marder W, McCune WJ. Advances in immunosuppressive therapy. Semin Respir Crit Care Med 2007;28:398-417.
9. Bartlett RR, Dimitrijevic M, Mattar T, et al. Leflunomide (HWA 486), a novel immunomodulating compound for the treatment of autoimmune disorders and reactions leading to transplantation rejection. Agents Actions 1991;32:10-21.
10. Gregory CR, Stewart A, Sturges B, et al. Leflunomide effectively treats naturally occurring immune-mediated and inflammatory diseases of dogs that are unresponsive to conventional therapy. Transplant Proc 1998;30:4143-4148. (Pubitemid 29013187)
11. Inokuma S, Sato T, Sagawa A, et al. Proposals for leflunomide use to avoid lung injury in patient with rheumatoid arthritis. Mod Rheumatol 2008;18:442-446.
12. Ranganath VK, Furst MD. Disease-modifying antirheumatic drug use in the elderly rheumatoid arthritis patient. Rheum Dis Clin North Am 2007;33:197-217.
13. Silva HT, Morris RE. Leflunomide and malononitriloamides. Expert Opin investig Drugs 1997;6:51-64.
14. Bohanec Grabar P, Rozman B, Tomsic M, et al. Genetic polymorphism of CYP1A2 and the toxicity of leflunomide treatment in rheumatoid arthritis patients. Eur J Clin Pharmacol 2008;64:871-876.
15. Holtmann MH, Gerts A-L, Weinman A, et al. Treatment of Crohn's disease with leflunomide as second-line immunosuppression; A phase I open-label trial on efficacy, tolerability and safety. Dig Dis Sci 2008;53:1025-1032.
16. Nguyen M, Kabir M, Ravaud R Short-term efficacy and safety of leflunomide in the treatment of active rheumatoid arthritis in everyday clinical use; open-label, prospective study. Clin Drug Investig 2004;24:103-112. (Pubitemid 38316599)
17. Muir P, Oldenhoff WE, Hudson AP, et al. Detection of DNA from a range of bacterial species in the knee joints of dogs with inflammatory knee arthritis and associated degenerative anterior cruciate ligament rupture. Microb Pathog 2007;42:47-55. (Pubitemid 46283321)
18. MacWilliams PS, Friedrichs KR. Laboratory evaluation and interpretation of synovial fluid. Vet Clin North Am Small Anim Pract 2003;33:153-178.
19. Schrader SC. The use of the laboratory in the diagnosis of joint disorders of dogs and cats. In: Kirk RW, Bonagura JD, eds. Current veterinary therapy XlI. Philadelphia: WB Saunders Co, 1995;1166-1171.
20. Hewicker-Trautwein M, Carter SD, Bennett D, et al. Immunocytochemical demonstration of lymphocyte subsets and MHC class II antigen expression in synovial membranes from dogs with rheumatoid arthritis and degenerative joint disease. Vet Immunol Immunopathol 1999;67:341-357. (Pubitemid 29147300)
21. Hegemann N, Wondimu A, Kohn B, et al. Cytokine profile in canine immune-mediated polyarthritis and osteoarthritis. Vet Comp Orthop Traumato! 2005;18:67-72. (Pubitemid 40814254)
22. Sakkas LI, Platsoucas CD. The role of T cells in the pathogenesis of osteoarthritis. Arthritis Rheum 2007;56:409-424.
23. Gregory CR, Silva HT, Patz JD, et al. Comparative effects of malononitriloamide analogs of leflunomide on whole blood lymphocyte stimulation in humans, rhesus macaques, cats, dogs, and rats. Transplant Proc 1998;30:1047-1048.
24. Chong AS-F, Huang W, Liu W, et al. In vivo activity of leflunomide: pharmacokinetic analyses and mechanism of immunosuppression. Transplantation 1999;68:100-109. (Pubitemid 29352839)
25. Kirsch BM, Zeyda M, Stuhlmeler K, et al. The active metabolite of leflunomide, A77 1726, interferes with dendritic cell function. Arthritis Res Ther 2005;7:R694-R703.
26. WilliamsJW, Xiao F, Foster P, et al. Leflunomide in experimental transplantation. Transplantation 1994;57:1223-1231.
27. Mattar T, Kochhar K, Bartlett R, et al. Inhibition of the epidermal growth factor receptor tyrosine kinase activity by leflunomide. FEBS Lett 1993;334:161-164. (Pubitemid 23330574)
28. Lirtzman RA, Gregory CR, Levitski RE, et al. Combined immunosuppression with leflunomide and cyclosporine prevents MLR-mismatched renal allograft rejection in a mongrel canine model. Transplant Proc 1996;28:945-947.
29. McChesney LP, Xiao F, Sankary HN, et al. An evaluation of leflunomide in the canine renal transplantation model. Transplantation 1994;57:1717-1722. (Pubitemid 24206409)
30. Affolter VK, Moore PE Canine cutaneous and systemic histiocytosis: reactive histiocytosis of dermal dendritic cells. Am J Dermatopathol 2000;22:40-48.
31. Yu LP, Smith GN Jr, Hasty KA, et al. Doxycycline inhibits type Xl collagenolytic activity of extracts from human osteoarthritic cartilage and of gelatinase. J Rheumatol 1991;18:1450-1452.
32. Smith GN Jr, Brandt KD, Hasty KA. Activation of recombinant human neutrophil procollagenase in the presence of doxycycline results in fragmentation of the enzyme and loss of enzyme activity. Arthritis Rheum 1996;39:235-244.
33. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: effects on nitric oxide synthases. Proc Natl Acad Sci USA 1996;93:14014-14019. (Pubitemid 26424237)
34. Lotz M. The role of nitric oxide in articular cartilage damage. Rheum Dis Clin North Am 1999;25:269-282. (Pubitemid 29267883)
35. Chan V, Tett SE. How is leflunomide prescribed and used in Australia? Analysis of prescribing and adverse effect reporting. Pharmacoepidemiol Drug Saf 2006;15:485-493. (Pubitemid 44150871)
36. Lee S-S, Park Y-W, Park JJ, et al. Combination treatment with leflunomide and methotrexate for patients with active rheumatoid arthritis. ScandJ Rheumatol 2009;38:11-14.
37. Malesci D, Tirri R, Buono R, et al. Leflunomide in psoriatic arthritis: a retrospective study of discontinuation rate in daily clinical practice compared with methotrexate. Clin Exp Rheumatol 2007;25:881-884. (Pubitemid 351166441)